Evidence map›Paper›PMID 35514680›Full record

ArticleRSC advances2019

Retracted Article: Gemcitabine aggravates miR-199a-5p-mediated breast cancer cell apoptosis by promoting VEGFA downregulation

Dingmei Deng, Xian Ye, Xiyue Wang, Guangning He

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Dingmei DengDepartment of Breast Surgery, Affiliated Dongguan People's Hospital, Southern Medical University No. 3, South Wandao Road, Wanjiang District 523059 Dongguan Guangdong P. R. China dengdingding0413@163.com +86-0769-28637111.ORCID 0000-0001-9527-5741
Xian YeDepartment of Breast Surgery, Affiliated Dongguan People's Hospital, Southern Medical University No. 3, South Wandao Road, Wanjiang District 523059 Dongguan Guangdong P. R. China dengdingding0413@163.com +86-0769-28637111.
Xiyue WangDepartment of Breast Surgery, Affiliated Dongguan People's Hospital, Southern Medical University No. 3, South Wandao Road, Wanjiang District 523059 Dongguan Guangdong P. R. China dengdingding0413@163.com +86-0769-28637111.
Guangning HeDepartment of Breast Surgery, Affiliated Dongguan People's Hospital, Southern Medical University No. 3, South Wandao Road, Wanjiang District 523059 Dongguan Guangdong P. R. China dengdingding0413@163.com +86-0769-28637111.
Dongguan People’s Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the most frequent malignancy diagnosed in women, and Gemcitabine-based therapy is frequently used to treat late-stage breast cancer. miR-199a-5p plays a tumor-suppressive role in breast cancer. This work aimed to explore the mechanism of miR-199a-5p plus Gemcitabine in breast cancer cells. Expression of miR-199a-5p was measured by RT-qPCR, while expression of vascular endothelial growth factor A (VEGFA) was measured by Western blot and RT-qPCR. Overexpression of miR-199a-5p and/or silencing of VEGFA was obtained using transfection in breast cancer cells (MCF-7 and MDA-MB-231). Functional experiments were performed to explore cell viability, apoptosis rate, and expressions of apoptosis-related genes: cell viability was assessed by MTT staining, apoptosis rate was recorded by flow cytometry, and Western blot was used to evaluate the expressions of Bcl-2, Bax and cleaved caspase 3. The signaling pathway was studied with respect to AKT activity

Identifiers

PMID35514680
PMCPMC9065560
OpenAlexW2955121053

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.